Michael Fuchs

Michael Fuchs

Auto-generated profile, based on publicly available information

Michael Fuchs

Max-Planck-Institut für Kohlenforschung, 45470 Mülheim/Ruhr (Germany)

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2015 in European Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
MFMichael Fuchs
Michael Fuchs
JFJudith E. Farnberger
Judith E. Farnberger
WKWolfgang Kroutil
Wolfgang Kroutil
During the last decade the use of ω‐transaminases has been identified as a very powerful method for the preparation of optically pure amines from the corresponding ketones. Their immense potential for the preparation of chiral amines, together with their ease of use in combination with existing biocatalytic methods, have made these biocatalysts a competitor to any chemical methodology for (asymmetric) amination. An increasing number of examples, especially from industry, shows that this biocatalytic technology outmaneuvers existing chemical processes by its simple and flexible nature. In the last few years numerous publications and patents on synthetic routes, mainly to pharmaceuticals, involving ω‐transaminases have been published. The review gives an overview of the application of ω‐transaminases in organic synthesis with a focus on active pharmaceutical ingredients (APIs) and the developments during the last few years.

9 August 2012 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
JSJohann H. Sattler
Johann H. Sattler
MFMichael Fuchs
Michael Fuchs
KTKatharina Tauber
Katharina Tauber
FMFrancesco G. Mutti
Francesco G. Mutti
KFKurt Faber
Kurt Faber
WKWolfgang Kroutil
Wolfgang Kroutil

31 August 2015 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MLMarkus Leutzsch
Markus Leutzsch
LWLarry M. Wolf
Larry M. Wolf
PGPuneet Gupta
Puneet Gupta
MFMichael Fuchs
Michael Fuchs
WTWalter Thiel
Walter Thiel
AFAlois Fürstner
Alois Fürstner
Insights into the mechanism of the unusual trans‐hydrogenation of internal alkynes catalyzed by {Cp*Ru} complexes were gained by para‐hydrogen (p‐H2) induced polarization (PHIP) transfer NMR spectroscopy. It was found that the productive trans‐reduction competes with a pathway in which both H atoms of H2 are delivered to a single alkyne C atom of the substrate while the second alkyne C atom is converted into a metal carbene. This “geminal hydrogenation” mode seems unprecedented; it was independently confirmed by the isolation and structural characterization of a ruthenium carbene complex stabilized by secondary inter‐ligand interactions. A detailed DFT study shows that the trans alkene and the carbene complex originate from a common metallacyclopropene intermediate. Furthermore, the computational analysis and the PHIP NMR data concur in that the metal carbene is the major gateway to olefin isomerization and over‐reduction, which frequently interfere with regular alkyne trans‐hydrogenation.

15 February 2010 in Advanced Synthesis & Catalysis
Verified
Journal Article
Closed access
PDF file
MFMichael Fuchs
Michael Fuchs
WGWalter Goessler
Walter Goessler
CPChristian Pilger
Christian Pilger
CKC. Kappe
C. Kappe

22 January 2013 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
KTKatharina Tauber
Katharina Tauber
MFMichael Fuchs
Michael Fuchs
JSJohann H. Sattler
Johann H. Sattler
JPJulia Pitzer
Julia Pitzer
DPDesiree Pressnitz
Desiree Pressnitz
WKWolfgang Kroutil
Wolfgang Kroutil

11 May 2010 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
MFMichael Fuchs
Michael Fuchs
DKDominik Koszelewski
Dominik Koszelewski
KTKatharina Tauber
Katharina Tauber
WKWolfgang Kroutil
Wolfgang Kroutil
KFKurt Faber
Kurt Faber
A straightforward, high-yielding, chemoenzymatic total synthesis of enantiopure (S)-Rivastigmine was developed using various ω-transaminases for the asymmetric amination of appropriate acetophenone precursors. Optimisation of the biotransformation allowed scale-up and the total synthesis of (S)-Rivastigmine.